FDA can do more to en­sure di­ver­si­ty in clin­i­cal tri­als, ex­perts say — in­clud­ing some con­struc­tive bad­ger­ing

The Covid-19 vac­cine and ther­a­peu­tic de­vel­op­ment races have opened many eyes to the re­al­i­ty that clin­i­cal tri­als in the US rarely in­clude the ap­pro­pri­ate num­bers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER